| 1. |
- Mauri, Davide, et al.
(författare)
-
Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy : Time to Rethink Our Approach
- 2022
-
Ingår i: Oncology Research and Treatment. - : S. Karger. - 2296-5270 .- 2296-5262. ; 45:4, s. 216-220
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Management of Ras wild-type colorectal cancer (CRC) patients upon disease progression after the successful use of targeted treatment with anti-EGFR monoclonal antibodies and backbone chemotherapy remains a clinical challenge.Summary: Development of treatment resistance with prevalence of preexisting RAS mutated clones, RAS mutation conversion, truncation of extracellular receptor domains as well as HER2 and MET amplification are molecular events that can be difficult to follow without the use of sophisticated laboratory techniques. The clinical hurdle of re-biopsy and tumor heterogeneity can be overcome by the implementation of next-generation sequencing (NGS) to analyze circulating tumor DNA (ctDNA) and identify druggable mutations or recovery of RAS-wildness. In this opinion paper, we summarize with critical thinking the clinical approach to be followed after the failure of first-line treatment in Ras wild-type CRC tumors with the use of NGS. Rechallenge with anti-EGFR inhibitors, in case of persistent or recovery of RAS-wildness, and targeted approach of specific mutations (BRAF inhibitors), amplifications (anti-Her2 treatment), or fusion proteins (NTRK inhibitors) can by guided by the use of NGS. The use of NGS platforms for serial analysis of ctDNA is an important step to better understand the molecular landscape of metastatic CRC and guide clinical decisions.Key Messages: NGS should be considered a mainstay in clinical practice for the management of CRC patients and health authorities should consider reimbursing its use in the appropriate clinical settings.
|
|
| 2. |
- Phillips, Frank, et al.
(författare)
-
Orofacial Granulomatosis associated with Crohn's Disease : a multi-centre case series
- 2022
-
Ingår i: Journal of Crohn's & Colitis. - : Elsevier. - 1873-9946 .- 1876-4479. ; 16:3, s. 430-435
-
Tidskriftsartikel (refereegranskat)abstract
- BACKGROUND: Orofacial granulomatosis (OFG) is a rare syndrome that may be associated with Crohn's disease (CD). We aimed to characterise this relationship and the management options in the biologic era.METHODS: This multicentre case series was supported by the European Crohn's and Colitis Organisation (ECCO), and performed as part of the Collaborative Network of Exceptionally Rare case reports (CONFER) project. Clinical data were recorded in a standardised collection form.RESULTS: This report includes 28 patients with OFG associated with CD: 14 males (mean age of 32 years, ±12.4 SD) and 14 females (40.3 years, ±21.0 SD). Non-oral upper gastrointestinal tract involvement was seen in 6 cases and perianal disease in 11. The diagnosis of OFG was made prior to CD diagnosis in 2 patients, concurrently in 8 and after CD diagnosis in 18. The distribution of OFG involved the lips in 16 cases and buccal mucosa in 18. Pain was present in 25 cases, with impaired swallowing or speaking in 6. Remission was achieved in 23 patients, notably with the use of anti-TNFs in 9 patients, vedolizumab in 1, ustekinumab in 1 and thalidomide in 2. A further 5 cases were resistant to therapies including anti-TNFs.CONCLUSION: OFG associated with CD may occur before, concurrently or after the diagnosis of CD. Perianal and UGI disease are common associations and there is a significant symptom burden in many. Remission can be obtained with a variety of immunosuppressive treatments, including several CD approved biologicals.
|
|
| 3. |
- Alexandropoulos, G. C., et al.
(författare)
-
Smart Wireless Environments Enabled by RISs: Deployment Scenarios and Two Key Challenges
- 2022
-
Ingår i: 2022 Joint European Conference on Networks and Communications and 6G Summit, EuCNC/6G Summit 2022. ; , s. 1-6
-
Konferensbidrag (refereegranskat)abstract
- Reconfigurable Intelligent Surfaces (RISs) constitute the enabler for programmable propagation of electromagnetic signals, and are lately being considered as a candidate physicallayer technology for the demanding connectivity, reliability, localization, and sustainability requirements of next generation wireless communications networks. In this paper, we present various deployment scenarios for RIS-enabled smart wireless environments that have been recently designed by the ongoing EU H2020 RISE-6G project. The scenarios are taxonomized according to performance objectives, in particular, connectivity and reliability, localization and sensing, as well as sustainability and secrecy. We identify various deployment strategies and sketch the core architectural requirements in terms of RIS control and signaling, depending on the RIS hardware architectures and their respective capabilities. Furthermore, we introduce and discuss, via preliminary simulation results and reflectarray measurements, two key novel challenges with RIS-enabled smart wireless environments, namely, the area of influence and the bandwidth of influence of RISs, which corroborate the need for careful deployment and planning of this new technology.
|
|
